However, with several applications of MEK inhibitors for complications in NF1, there may be more interest in utilizing MEK inhibitor as first line-therapy in circumstances when multiple disease types may be addressed with single agent therapy, such as a MEK inhibitor for simultaneous pLGG and plexiform neurofibroma treatment. Here, MAP2K7 is linked to neurofibromatosis type 1.